Literature DB >> 25499602

Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18).

Sally E Jensen1, Karen Kaiser2, Leilani Lacson2, Julian Schink3, David Cella4.   

Abstract

OBJECTIVE: This study examined the content validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), an advanced ovarian cancer symptom index comprised of symptoms perceived as most important by clinical experts and women with advanced ovarian cancer.
METHODS: Eighteen women with advanced ovarian cancer completed the NFOSI-18 and participated in cognitive interviews to assess: (a) the understandability of the NFOSI-18; and (b) the things patients have in mind when responding to the item, "I am bothered by side effects of treatment;" and (c) the interpretation patients place on items relating to fatigue and lack of energy. Interviews were recorded and transcribed for qualitative analysis.
RESULTS: All but 2 (89%) participants indicated that each item was clear and understandable and the same proportion (89%) stated they were "very confident" or "confident" about providing accurate answers to all but one item. When responding to the item, "I am bothered by side effects of treatment," fatigue, nausea, and neuropathy constituted the most frequently mentioned concerns. Among the participants who were asked, eight participants responded that "fatigue" and "lack of energy" were the same concept and nine responded they were different. Participants associated "fatigue" with tiredness and associated "lack of energy" with the inability to perform daily tasks and activities.
CONCLUSIONS: The findings support the content validity of the NFOSI-18. Item revisions, deletions or additions do not appear warranted. Future research can address the reliability and validity of the NFOSI-18 in clinical research.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Content validity; Ovarian cancer; Patient-reported outcome; Quality of life; Symptom index

Mesh:

Year:  2014        PMID: 25499602     DOI: 10.1016/j.ygyno.2014.12.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

2.  Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Authors:  Joyce F Liu; Mark F Brady; Ursula A Matulonis; Austin Miller; Elise C Kohn; Elizabeth M Swisher; David Cella; William P Tew; Noelle G Cloven; Carolyn Y Muller; David P Bender; Richard G Moore; David P Michelin; Steven E Waggoner; Melissa A Geller; Keiichi Fujiwara; Stacy D D'Andre; Michael Carney; Angeles Alvarez Secord; Katherine M Moxley; Michael A Bookman
Journal:  J Clin Oncol       Date:  2022-03-15       Impact factor: 50.717

3.  Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials.

Authors:  Sara Shaunfield; Sally Jensen; Allison P Fisher; Kimberly Webster; Shohreh Shahabi; Arijit Ganguli; David Cella
Journal:  Health Qual Life Outcomes       Date:  2019-12-19       Impact factor: 3.186

4.  Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Authors:  Maria Lee; Yumi Lee; Kidong Kim; Eun Young Park; Myong Cheol Lim; Jung-Sup Kim; Hee Seung Kim; Yong-Beom Kim; Yong-Man Kim; Jungnam Joo; Sang Yoon Park; Chel Hun Choi; Jae-Hoon Kim
Journal:  Cancer Res Treat       Date:  2018-03-07       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.